Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Bought by Old West Investment Management LLC

Old West Investment Management LLC raised its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 617.2% during the third quarter, HoldingsChannel.com reports. The firm owned 340,441 shares of the biopharmaceutical company’s stock after buying an additional 292,976 shares during the period. Amicus Therapeutics makes up about 1.4% of Old West Investment Management LLC’s portfolio, making the stock its 22nd biggest holding. Old West Investment Management LLC’s holdings in Amicus Therapeutics were worth $3,636,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in FOLD. Wellington Management Group LLP raised its position in shares of Amicus Therapeutics by 13.5% in the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after purchasing an additional 2,856,101 shares in the last quarter. Millennium Management LLC raised its position in shares of Amicus Therapeutics by 1,758.9% during the 2nd quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company’s stock valued at $18,790,000 after acquiring an additional 1,792,277 shares in the last quarter. William Blair Investment Management LLC raised its position in shares of Amicus Therapeutics by 12.8% during the 2nd quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock valued at $128,993,000 after acquiring an additional 1,477,084 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at approximately $13,530,000. Finally, Assenagon Asset Management S.A. raised its position in shares of Amicus Therapeutics by 141.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company’s stock valued at $21,765,000 after acquiring an additional 1,192,489 shares in the last quarter.

Insider Activity at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $8,884,273.08. This trade represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold 30,401 shares of company stock valued at $339,363 over the last 90 days. 2.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

FOLD has been the topic of several research reports. JPMorgan Chase & Co. upped their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Jefferies Financial Group initiated coverage on Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 price target on the stock. StockNews.com raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, November 7th. Finally, Guggenheim increased their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.63.

Amicus Therapeutics Trading Up 3.1 %

NASDAQ:FOLD opened at $10.13 on Wednesday. Amicus Therapeutics, Inc. has a 1 year low of $9.02 and a 1 year high of $14.57. The stock has a market cap of $3.03 billion, a price-to-earnings ratio of -29.79 and a beta of 0.60. The business has a fifty day moving average of $10.56 and a 200-day moving average of $10.61. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.